EGFR-IN-210

EGFR-IN-210 (Compound T6) exhibits broad-spectrum antiproliferative activity in the NCI-60 cell panel, with an average growth inhibition rate exceeding 100% across 5 cancer subtypes and a maximum inhibition rate of up to 200% in individual sensitive cell lines^[1].
EGFR-IN-210 (0.53 μM; 48 h) potently inhibits the migration of HT29 colon cancer cells, reducing the wound healing rate to 16.85% within 48 h^[1].
EGFR-IN-210 (0.53 μM; 1-3 weeks) potently inhibits the long-term proliferation and colony-forming abilities of HT29 colorectal cancer cells^[1].
EGFR-IN-210 (0.53 μM; 24 h) induces G₀/G₁ cell cycle arrest in HT29 colorectal cancer cells, reduces the proportion of S-phase cells, while maintaining G₂/M-phase cell levels comparable to those of the untreated control group^[1].
EGFR-IN-210 (0.53 μM; 24 h) induces significant apoptosis in HT29 colorectal cancer cells, with a total apoptosis rate of 67.40%, and this process is mainly mediated via the late apoptosis pathway^[1].
EGFR-IN-210 (48 h) exhibits favorable in vitro safety profiles, with low cytotoxicity against normal WI-38 human lung fibroblasts (IC₅₀: 156.59 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.